Literature DB >> 20813009

Silencing of ROR1 and FMOD with siRNA results in apoptosis of CLL cells.

Aniruddha Choudhury1, Katja Derkow, Amir Hossein Daneshmanesh, Eva Mikaelsson, Shahryar Kiaii, Parviz Kokhaei, Anders Osterborg, Håkan Mellstedt.   

Abstract

We have previously demonstrated that ROR1 and FMOD (fibromodulin) are two genes upregulated in chronic lymphocytic leukaemia (CLL) cells compared to normal blood B cells. In this study, siRNAs were used to specifically silence ROR1 and FMOD expression in CLL cells, healthy B cells and human fibroblast cell lines. siRNA treatment induced a specific reduction (75-95%) in FMOD and ROR1 mRNA. Western blot analysis with specific antibodies for FMOD and ROR1 demonstrated that the proteins were significantly downregulated 48 h after siRNA treatment. Silencing of FMOD and ROR1 resulted in statistically significant (P ≤ 0·05-0·001) apoptosis of CLL cells but not of B cells from normal donors. Human fibroblast cell lines treated with FMOD and ROR1 siRNA did not undergo apoptosis. This is the first report demonstrating that ROR1 and FMOD may be involved in the survival of CLL cells. ROR1 in particular is further explored as potential target for therapy in CLL.
© 2010 Blackwell Publishing Ltd.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20813009     DOI: 10.1111/j.1365-2141.2010.08362.x

Source DB:  PubMed          Journal:  Br J Haematol        ISSN: 0007-1048            Impact factor:   6.998


  32 in total

Review 1.  The role of Ryk and Ror receptor tyrosine kinases in Wnt signal transduction.

Authors:  Jennifer Green; Roel Nusse; Renée van Amerongen
Journal:  Cold Spring Harb Perspect Biol       Date:  2014-02-01       Impact factor: 10.005

2.  Crosstalk between ROR1 and BCR pathways defines novel treatment strategies in mantle cell lymphoma.

Authors:  Hanna Karvonen; David Chiron; Wilhelmiina Niininen; Sara Ek; Mats Jerkeman; Elaheh Moradi; Matti Nykter; Caroline A Heckman; Olli Kallioniemi; Astrid Murumägi; Daniela Ungureanu
Journal:  Blood Adv       Date:  2017-11-09

3.  High-level ROR1 associates with accelerated disease progression in chronic lymphocytic leukemia.

Authors:  Bing Cui; Emanuela M Ghia; Liguang Chen; Laura Z Rassenti; Christopher DeBoever; George F Widhopf; Jian Yu; Donna S Neuberg; William G Wierda; Kanti R Rai; Neil E Kay; Jennifer R Brown; Jeffrey A Jones; John G Gribben; Kelly A Frazer; Thomas J Kipps
Journal:  Blood       Date:  2016-11-04       Impact factor: 22.113

4.  Receptor affinity and extracellular domain modifications affect tumor recognition by ROR1-specific chimeric antigen receptor T cells.

Authors:  Michael Hudecek; Maria-Teresa Lupo-Stanghellini; Paula L Kosasih; Daniel Sommermeyer; Michael C Jensen; Christoph Rader; Stanley R Riddell
Journal:  Clin Cancer Res       Date:  2013-04-25       Impact factor: 12.531

Review 5.  Antithetic roles of proteoglycans in cancer.

Authors:  Elena Garusi; Silvia Rossi; Roberto Perris
Journal:  Cell Mol Life Sci       Date:  2011-10-02       Impact factor: 9.261

Review 6.  Engineered T cells: the promise and challenges of cancer immunotherapy.

Authors:  Andrew D Fesnak; Carl H June; Bruce L Levine
Journal:  Nat Rev Cancer       Date:  2016-08-23       Impact factor: 60.716

7.  Safety of targeting ROR1 in primates with chimeric antigen receptor-modified T cells.

Authors:  Carolina Berger; Daniel Sommermeyer; Michael Hudecek; Michael Berger; Ashwini Balakrishnan; Paulina J Paszkiewicz; Paula L Kosasih; Christoph Rader; Stanley R Riddell
Journal:  Cancer Immunol Res       Date:  2014-10-29       Impact factor: 11.151

Review 8.  WNT signalling pathways as therapeutic targets in cancer.

Authors:  Jamie N Anastas; Randall T Moon
Journal:  Nat Rev Cancer       Date:  2013-01       Impact factor: 60.716

9.  The onco-embryonic antigen ROR1 is expressed by a variety of human cancers.

Authors:  Suping Zhang; Liguang Chen; Jessica Wang-Rodriguez; Ling Zhang; Bing Cui; Wendy Frankel; Rongrong Wu; Thomas J Kipps
Journal:  Am J Pathol       Date:  2012-10-04       Impact factor: 4.307

10.  Autocrine Signaling by Wnt-5a Deregulates Chemotaxis of Leukemic Cells and Predicts Clinical Outcome in Chronic Lymphocytic Leukemia.

Authors:  Pavlina Janovska; Lucie Poppova; Karla Plevova; Hana Plesingerova; Martin Behal; Marketa Kaucka; Petra Ovesna; Michaela Hlozkova; Marek Borsky; Olga Stehlikova; Yvona Brychtova; Michael Doubek; Michaela Machalova; Sivasubramanian Baskar; Alois Kozubik; Sarka Pospisilova; Sarka Pavlova; Vitezslav Bryja
Journal:  Clin Cancer Res       Date:  2015-08-03       Impact factor: 12.531

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.